Unlocking Synthetic Lethality in DNA Damage Response. High-purity reagents for BLM-TOP3A-RMI complex disruption and genome stability research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RMI1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RMI1 Full-Length & TRD Domain Recombinant Protein. HEK293 expressed, >95% purity, Endotoxin <1 EU/µg. Sequence Verified. Ideal for PPI studies and ternary complex assembly. | View RMI1 Products |
| Gene Delivery | RMI1 Promise-ORF / Lentivirus Particles. Full-length ORF for nuclear localization studies. CMV or U6 promoter options. Ready for stable cell line construction. | View RMI1 Products |
| Knockdown Validator | RMI1 siRNA Set (3 pre-validated sequences). For synthetic lethality verification and specificity controls. | View RMI1 Products |
| Benchmark Ab | Anti-RMI1 Monoclonal Antibody (Recombinant). Research-grade positive control for Western, IP, and IHC. Sequence Verified. | View RMI1 Products |
| Complex Partner: BLM | BLM Helicase. Direct binding partner; core component of BTR complex. Essential for Holliday junction dissolution. | View BLM Products |
| Complex Partner: TOP3A | TOP3A (Topoisomerase III-alpha). Catalytic partner; essential for RMI1-mediated DNA repair. | View TOP3A Products |
| Paralog: RMI2 | RMI2. Heterodimeric partner required for complex stability and nuclear localization. | View RMI2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| BTR Complex Reconstitution & Ternary Complex Assembly | High-purity RMI1, BLM, TOP3A proteins available; Sequence Verified; HEK293 expressed for native folding; matched buffer systems. |
| Synthetic Lethality Screening (PARP/i combinations) | High-efficiency RMI1 siRNA Set (3 pre-validated sequences) for CRISPR/siRNA synthetic lethal validation. |
| Nuclear Localization Verification | Lentivirus delivery system with NLS optimization; Ready for stable cell line construction and live-cell imaging. |
| Specificity vs. RMI2 Paralog | RMI1-specific epitope antibodies; cross-reactivity panel including RMI2 and OBFC1 proteins for selectivity assays. |
| Ortholog Cross-reactivity (Mouse models) | Human/Mouse RMI1 ortholog proteins available with >95% purity for species bridging studies. |
| Off-target Counter-screening (OB-fold family) | Homolog panel (RMI1, RMI2, OBFC1) strictly verified by mass spec for selectivity assays. |
Live RMI1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Synthetic Lethality Research
- ➤ DNA Repair Mechanism Studies
- ➤ Drug Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The targeting of RMI1 represents a strategic expansion in the DNA Damage Response (DDR) inhibitor landscape. As resistance to first-generation PARP inhibitors drives clinical failures, the industry is pivoting toward synthetic lethal combinations targeting the BLM-TOP3A-RMI complex. RMI1, as the scaffold organizing this Holliday junction dissolution machinery, offers a unique protein-protein interaction (PPI) node for therapeutic intervention. The race for RMI1 modulators is intensifying, with major players shifting focus from catalytic inhibitors to complex disruption strategies and targeted protein degradation (PROTACs). As first-generation DDR therapies reach resistance barriers, the next wave of R&D is targeting RMI1-dependent alternative lengthening of telomeres (ALT) and fork protection mechanisms in BRCA-deficient tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PPI Disruptor (Small Mol) | AstraZeneca, Merck, Artios Pharma | BRCA-mutant Ovarian/Prostate Cancer | Ternary Complex Assembly (BLM-TOP3A-RMI1) - Need pure RMI1 domains |
| Synthetic Lethal Combo | Pfizer, Bristol Myers Squibb | PARP-resistant Solid Tumors | siRNA knockdown efficiency assays for combination validation |
| PROTAC/Degrader | Arvinas, C4 Therapeutics | ALT-positive Sarcomas | Cellular localization & stability assays (Lentivirus-based) |
| Biomarker Assay | Myriad Genetics, Foundation Medicine | Patient Stratification | High-specificity IHC antibodies with defined epitopes |